EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Alizé Pharma 3 raised a €67 million ($75 million) series A round. The French biotech will use the money to move two candidates into the clinic next year. Statement (PDF)

> Johnson & Johnson returned the rights to anti-CD40 antibody ADC-1013 to Alligator Bioscience. J&J took the drug through a phase 1 trial before deciding to prioritize other assets. Release 

> A phase 3 trial of Atlantic Healthcare’s Camligo in orphan-designated pouchitis missed its co-primary endpoints. Despite the failure, Atlantic plans to meet with regulators to discuss a pathway to approval. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Regulators on both sides of the Atlantic granted orphan drug designation to Genfit’s elafibranor in primary biliary cholangitis. Genfit plans to start a phase 3 trial in the indication later this year. Release 

> Iontas entered into an antibody optimization deal with Teva. The work will focus on antibodies against a defined target of interest to Teva. Statement 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.